Oppenheimer initiated coverage on Xeris Biopharma with a new price target
$XERS
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer initiated coverage of Xeris Biopharma with a rating of Outperform and set a new price target of $5.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/12/2025 | $10.00 | Buy | H.C. Wainwright |
| 11/11/2024 | $3.00 | Overweight → Neutral | Piper Sandler |
| 3/28/2024 | $5.00 | Outperform | Oppenheimer |
| 8/28/2023 | $4.50 | Buy | Craig Hallum |
| 10/21/2022 | $4.00 | Buy | Jefferies |
| 4/28/2022 | $6.50 | Buy | Craig Hallum |
| 2/16/2022 | $8.00 → $6.00 | Outperform | SVB Leerink |
| 12/31/2021 | $6.00 → $8.00 | Outperform | SVB Leerink |
H.C. Wainwright resumed coverage of Xeris Biopharma with a rating of Buy and set a new price target of $10.00
Piper Sandler downgraded Xeris Biopharma from Overweight to Neutral and set a new price target of $3.00
Oppenheimer initiated coverage of Xeris Biopharma with a rating of Outperform and set a new price target of $5.00
144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
10-Q - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
Total revenue increased 49% YoY to $71.5 million; Recorlev® revenue grew 136% YoY Raises full-year 2025 total revenue guidance to $280-$290 million from previous range of $260-$275 million Provided long-term outlook at Analyst and Investor Day in June Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter ended June 30, 2025, and updated its fiscal 2025 guidance. "Total revenue in the second quarter increased almost 50%
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2025 financial results before the open of the U.S. financial markets on Thursday, August 7, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login/LE9zwo3gmwDLA5JeSSHtiUIAhliB0lMHV58 After registering, a confirmation email
Company to discuss long-range financial outlook and strategic roadmap for rapid and sustainable growth Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation. "We have built a strong foundation through innovation and a relentless commitment to improving patient lives. We will showcase how these achievements have positioned us to take the next bold step in our journey of growth and transformation. We are excited to sh
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)
SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ
Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and strategic direction for the Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions, reporting to John Shannon, X
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track record of its leadership team Q2 '24 total revenue is anticipated to exceed $47 million, representing more than 23% growth over last year Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced a CEO succession plan effective August 1, 20
SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G/A - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)
Total revenue increased 49% YoY to $71.5 million; Recorlev® revenue grew 136% YoY Raises full-year 2025 total revenue guidance to $280-$290 million from previous range of $260-$275 million Provided long-term outlook at Analyst and Investor Day in June Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter ended June 30, 2025, and updated its fiscal 2025 guidance. "Total revenue in the second quarter increased almost 50%
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2025 financial results before the open of the U.S. financial markets on Thursday, August 7, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login/LE9zwo3gmwDLA5JeSSHtiUIAhliB0lMHV58 After registering, a confirmation email
Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3rd in New York City Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. "We're very pleased with our strong start to the year,